直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – February 2017

February 07, 2017

Authored and Edited by Caitlin E. Fowler; Elizabeth D. Ferrill; Lauren J. Dreyer

Wednesday, February 8, 2017

Allergan v. Sandoz, No. 16-1085, Courtroom 201

In this appeal, the Federal Circuit will determine whether collateral estoppel can bar a party from asserting an infringement claim when, in previous litigation between the parties, a patent in the same family and covering the same product was held invalid.  Allergan argues that collateral estoppel should not apply in this case because the issue of the validity of the eyelash growth and eyelash darkness claims is not “identical.”  Sandoz argues that collateral estoppel should apply in this case because the two sets of claims are “substantially similar,” thus the issue is “identical.”

Intellectual Ventures II v. Ericsson, No. 16-1739, Courtroom 201

In this appeal, the Federal Circuit will address Intellectual Ventures’ argument that it was denied notice and opportunity to present rebuttal evidence required by the Administrative Procedure Act when the PTAB adopted a claim construction never argued by either party.  The Court will also address whether the PTAB erred in adopting a combination of references that Ericsson expressly abandoned and then supplying its own theory for motivation to combine.

Thursday, February 9, 2017

Phil-Insul v. Airlite Plastics, No. 16-1982, Courtroom 201

In this case, the Federal Circuit is tasked with deciding whether its own Rule 36 decisions constitute “final decisions” upon which collateral estoppel can be based.  Phil-Insul argues that the Court’s Tecsec decision stands for the proposition that Rule 36 judgments cannot have preclusive effect because the Court “does not endorse or reject any specific part of the trial court’s reasoning.” Airlite argues that the Federal Circuit rules clearly indicate that Rule 36 judgments are binding in the context of collateral estoppel.

NantKwest v. Lee, No. 16-1794, Courtroom 402

Should a dissatisfied applicant choose to pursue a civil action under 35 U.S.C. § 145, instead of appealing directly to the Federal Circuit, it must pay “all expenses of the proceedings.”  In this appeal from the E.D. Va., the Federal Circuit must decide whether the “all expenses” language allows the USPTO to recover its attorney’s fees despite the presumption that each litigant pays their own attorney’s fees.

Friday, February 10, 2017

Speck v. Bates, No. 16-1879, Courtroom 201 Speck appeals from a PTAB decision canceling the claims of an application on the grounds of interference estoppel.  Speck argues that the use of the closed-ended “consisting of” language in the interference claims precludes the application of estoppel to the appealed claims, which use the open-ended “comprising” language.  The appellees argue that the interference estoppel by judgment is warranted because the appealed claims are not “patentably distinct” from the interference claims.

Tags

Spotlight on Upcoming Oral Arguments

Contacts

Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

INCONTESTABLE® Blog

Netflix Prevails in Copyright Infringement Suit Regarding Tiger King

May 14, 2026

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP